The FDA has recently approved Aimovig (Erenumab) a once-a-month injection to prevent migraines. Aimovig is a monoclonal antibody that targets the calcitonin gene-related peptide receptor (CGRP). CGRP is a neurotransmitter that dilates blood vessels and stimulates pain. It was discovered that levels of CGRP go way up in people experiencing migraines. By blocking the receptor for CGRP the Aimovig is able to prevent headaches.
Since Aimovig is a preventative agent, it is currently only recommended for patients with frequent severe migraines or with chronic migraines. The cost of each injection is $600.00.